Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 29, 2023 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq:PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors approved a stock option grant to Ken Kobayashi, M.D., the Company’s newly appointed Chief Medical Officer, in connection with his employment with the Company effective on November 27, 2023. The equity award was granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of December 29, 2023, as an inducement material to Dr. Kobayashi entering into employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (PYXS)
- Today’s Top Performers: MoBot’s Market Review 10/09/25 02:00 PM
- Breaking News: MoBot’s Latest Update as of 10/09/25 01:00 PM
- MoBot alert highlights: NASDAQ: HTCR, NYSE: LDI, NASDAQ: RLMD, NASDAQ: PYXS, NASDAQ: CIGL (09/05/25 03:00 PM)
- Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
- Today’s Top Performers: MoBot’s Market Review 05/02/25 03:00 PM